Neurovasc Technologies Inc., of Laguna Hills, Calif., has entered a strategic partnership with the Wego Group that includes $34 million in funding to support the company’s product portfolio development and global clinical trial program. Specifically, the funding first will go toward studies of the company’s stent-retriever, designed to treat patients suffering an acute ischemic stroke, in markets such as Japan, the EU, U.S. and China.

BEIJING – Chinese biosimilar maker Bio-Thera Solutions Ltd., of Guangzhou, on Feb. 21 launched a pre-revenue listing on Shanghai’s STAR market to reap $241 million at a valuation of almost $2 billion.

DUBLIN – Advanced Biodesign SAS secured €9 million (US$9.8 million) in new funding commitments to take its lead drug candidate, ABD-3001, into a phase I trial in acute myeloid leukemia (AML). The Lyon, France-based firm is investigating a novel drug mechanism associated with cancer cell metabolism, which could have application across several cancer types.